SELLAS Life Sciences Group, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SELLAS Life Sciences Group, Inc.
Plus deals involving SELLAS/3D Medicines, Kyowa Kirin/InveniAI, JW/Voronoi, Y-mAbs/Takeda, Horizon Discovery/Sanyou, Sentinel Oncology/PharmaEngine
RXi thought it had solved the RNAi delivery issue but was focused on dermatology and ophthalmology. New CEO Dispersyn thought the platform offered more lucrative promise as a way of optimizing IO therapy.
Dutch biotech Amphera has progressed into late-stage clinical studies with dendritic cells activated with an allogeneic lysate of tumor cell lines; the dendritic cells are expected to have a therapeutic effect in patients with mesothelioma, a tumor with few treatment options.
Preparing to meet with FDA in December to plan next steps for NeuVax in triple-negative breast cancer, Sellas reveals 26-month data that show further clinical benefit compared with a 19-month interim look. Firm still hopes to out-license the vaccine candidate.
- Large Molecule
- Other Names / Subsidiaries
- Argonaut Pharmaceuticals, Inc.
- Galena Biopharma, Inc.
- RXi Pharmaceuticals Corporation